Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus + imatinib in PDGFRA-D842V unresectable or metastatic GIST
2010-020305-32Phase 2Terminated
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- May 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of everolimus and imatinib in gastrointestinal stromal tumor (GIST), sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Primary endpoint: Overall tumor response rate at 6 months. Started May 2010; status: terminated.
02
Drugs
everolimusimatinib
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on 2010-020305-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020305-32.